Shots:

• Entos to receive a $50M up front including an equity investment & is also eligible to receive ~$400M upon the achievement of development and commercial milestone for each program along with royalties
• The collaboration will combine Entos' Fusogenix nucleic acid delivery technology with Lilly's therapeutic to deliver nucleic acid therapies to the nervous system
• Entos will be responsible for the generation, development, and optimization of PLVs using its Fusogenix platform technology. Lilly will be responsible for selecting PLVs for clinical development and commercialization

Ref: Lilly | Image: Bilaterals